Mucopolysaccharidosis III (Sanfilippo Syndrome):Market View
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis III (Sanfilippo Syndrome) Therapeutics.
In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of MPS III, representing a large portion of global cases.
Currently, there is no cure for MPS III, and no disease-modifying therapies are available.
The MPS III pipeline holds 24 molecules, with only one asset in the pre-registration stage.
Over the past decade, 29 clinical trials have been conducted in MPS III. The highest number of studies were initiated in 2024.
During the past 24 months, five mergers and acquisitions and four strategic alliances involving companies developing MPS III assets were completed.
Scope
GlobalData’s Mucopolysaccharidosis III (Sanfilippo Syndrome): Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook